STOCK TITAN

Corbus (NASDAQ: CRBP) COO receives RSU and stock option grants in 2026

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. reported an equity compensation grant to its Chief Operating Officer, Ian Hodgson. On January 14, 2026, he received 28,365 restricted stock units (RSUs), which will be settled in common shares. These RSUs vest 25% on each of the first four anniversaries beginning January 14, 2027, with a provision for partial accelerated vesting if his service is terminated by the company without cause after the first vesting date.

On the same date, he was also granted 85,095 stock options with a $8.26 exercise price under the 2024 Equity Compensation Plan. Twenty‑five percent of this option vests on January 14, 2027, and the remaining 75% vests in equal monthly installments over 36 months starting February 14, 2027. Following these grants, he beneficially owned 54,342 shares of common stock, which include 53,108 unvested RSUs subject to their respective vesting schedules, and 85,095 options.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hodgson Ian

(Last) (First) (Middle)
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC
500 RIVER RIDGE DRIVE

(Street)
NORWOOD MA 02062

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.0001 per share 01/14/2026 A 28,365(1) A $0 54,342(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock options (right to buy) $8.26 01/14/2026 A 85,095 (3) 01/14/2036 Common Stock 85,095 $0 85,095 D
Explanation of Responses:
1. On January 14, 2026, the Reporting Person was granted 28,365 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on January 14, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.
2. This amount includes 53,108 unvested RSUs subject to each grant's vesting schedule as previously reported.
3. The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on January 14, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 14, 2027.
/s/ Meghan Houghton, attorney-in-fact for Ian Hodgson 01/16/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were reported in this Corbus (CRBP) Form 4?

The filing reports that Chief Operating Officer Ian Hodgson was granted 28,365 RSUs and 85,095 stock options on January 14, 2026 as part of his equity compensation.

How do the 28,365 RSUs granted to the Corbus (CRBP) COO vest?

The 28,365 RSUs vest in four equal installments of 25% each year, on the first, second, third and fourth anniversaries beginning on January 14, 2027, with a pro rata acceleration feature if his service is terminated by the company without cause after the first vesting date.

What are the key terms of the 85,095 stock options granted by Corbus (CRBP)?

The 85,095 stock options have a $8.26 exercise price. 25% vests on January 14, 2027, and the remaining 75% vests in equal monthly installments over 36 months starting on February 14, 2027, under the 2024 Equity Compensation Plan.

How many Corbus (CRBP) shares does the COO beneficially own after these grants?

After the reported transactions, the COO beneficially owned 54,342 shares of common stock, which include 53,108 unvested RSUs that remain subject to their respective vesting schedules.

Does the Corbus (CRBP) Form 4 indicate any purchase or sale of shares for cash?

No share purchases or sales for cash are reported. The Form 4 reflects equity awards (RSUs and stock options) granted at a reported price of $0 for the grants, consistent with typical compensation awards.

What triggers accelerated vesting of the Corbus (CRBP) COO’s RSUs?

If the COO’s service is terminated by the company without cause after the first vesting date, a pro rata portion of the RSUs scheduled to vest on the next vesting date will accelerate based on completed months of service since the most recent vesting date.

Corbus Pharmaceu

NASDAQ:CRBP

CRBP Rankings

CRBP Latest News

CRBP Latest SEC Filings

CRBP Stock Data

150.78M
16.31M
0.71%
81.85%
9.48%
Biotechnology
Pharmaceutical Preparations
Link
United States
NORWOOD